众生药业(002317) - 2021 Q3 - 季度财报

Revenue and Profit - Revenue for Q3 2021 reached ¥613,485,638.21, an increase of 16.85% year-over-year, while year-to-date revenue was ¥1,823,582,996.89, up 39.17% compared to the same period last year[4] - Net profit attributable to shareholders for Q3 2021 was ¥25,964,108.95, a decrease of 76.36% year-over-year, with year-to-date net profit at ¥313,762,527.56, an increase of 4.07%[4] - Net profit excluding non-recurring items for Q3 2021 was ¥89,661,165.37, up 48.19% year-over-year, and year-to-date net profit excluding non-recurring items was ¥297,096,525.00, an increase of 66.50%[4] - The company's total comprehensive income for the period attributable to shareholders was CNY 313,762,527.56, compared to CNY 301,480,673.30 in the previous period[41] - The total comprehensive income for the period was ¥333,693,891.15, compared to ¥301,282,422.49, reflecting an increase of approximately 10.73%[45] Assets and Liabilities - The total assets of the company rose from RMB 4.78 billion to RMB 5.02 billion, marking an increase of about 5%[29] - Total current assets decreased from RMB 3.13 billion to RMB 2.86 billion, reflecting a decline of approximately 8.5%[29] - Non-current assets increased from RMB 1.64 billion to RMB 2.16 billion, representing a growth of approximately 31.5%[29] - The company's total liabilities decreased to CNY 1,061,970,633.78 from CNY 1,149,590,398.01, a reduction of approximately 7.6%[38] - Total equity attributable to shareholders of the parent company rose to CNY 3,757,877,619.30 from CNY 3,524,977,152.62, an increase of about 6.6%[38] Cash Flow - The company’s cash flow from operating activities showed a decline of 10.72% year-to-date, totaling ¥321,952,847.34[4] - Cash inflow from operating activities totaled ¥1,882,857,421.78, compared to ¥1,687,011,237.18, reflecting an increase of about 11.59%[45] - The net cash flow from operating activities decreased to ¥321,952,847.34 from ¥360,592,483.17, a decline of approximately 10.67%[49] - Cash outflow from investment activities was ¥788,995,050.40, up from ¥505,575,928.97, marking an increase of about 55.73%[49] - The net cash flow from investment activities showed a significant decline to -¥650,387,170.38 from ¥253,767,531.91[49] Expenses and Investments - Research and development expenses increased by 49.72% to ¥87,165,221.92 from ¥58,217,499.18 year-on-year, reflecting ongoing investment in R&D[15] - Financial expenses decreased by 79.60% to ¥3,034,353.30, influenced by reduced financing interest expenses and increased interest income from deposits[15] - The company experienced an 82.02% decline in investment income, reporting ¥17,962,238.45 compared to ¥99,919,897.20 in the previous year, mainly due to gains from the disposal of subsidiaries recognized last year[15] Shareholder Actions - The company repurchased shares totaling approximately RMB 51.59 million, acquiring 5,927,093 shares, which is 0.73% of the total share capital, at a price range of RMB 8.26 to RMB 9.09 per share[23] - The company plans to use the repurchased shares for employee stock ownership plans or equity incentives[23] - The company approved the write-off of bad debts amounting to RMB 31.50 million, which had already been fully provisioned, and expects to recognize an increase in profit of RMB 1.98 million from recovered amounts[27] Changes in Financial Position - The company reported a significant increase in other current assets by 200.95% to ¥132,140,196.18 due to an increase in large certificates of deposit[12] - The construction in progress increased by 159.51% to ¥59,657,886.40, reflecting increased investment in production facilities[12] - Long-term prepaid expenses surged by 2761.79% to ¥6,650,819.31, attributed to renovation expenses for leased fixed assets[12] - The company experienced a 36.67% decrease in accounts payable to ¥56,225,259.38, due to payments made for large raw material purchases from the previous year[12] Fair Value Changes - The company reported a significant loss in fair value changes of financial assets, amounting to -¥93,272,013.57 during the reporting period[7] - The fair value change of other equity instruments increased by 988.54% to ¥26,514,700.84, reflecting significant fair value changes in invested industrial funds during the reporting period[15] - The company reported a significant increase in other comprehensive income, which rose by 146.87% to ¥44,536,973.91, attributed to fair value changes in invested industrial funds[15]